Despite advances in targeted cancer therapies, there’s still a need for screening tools that quickly match patients with effective treatments while minimizing side effects. Autoantibody profiling may offer a solution.
Cancer cells can trigger an immune response, producing autoantibodies against tumor-associated antigens, often before symptoms appear. These autoantibody signatures can help identify treatment responders and predict patients at risk for adverse events.
Explore how cancer and its treatments trigger autoantibody production—and how researchers use these insights to advance drug development and patient care—in our comprehensive white paper.
